Insider buying last 90 days
No open-market insider purchases were filed for MCK in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every MCK insider filing, plotted on the chart in Gekko.Open MCK in Gekko
NYSE: MCK
McKesson (MCK) Stock Analysis & Forecast
$874.65−4.92 (−0.6%)
Close on Sep 18, 2026. Page updated Sep 19, 9:16 pm ET.
Gekko Brief
AI summaryMcKesson trades at $874.65, down 0.6% on the day, and sits above both its 50-day average of $866.63 and its 200-day average of $844.14. The stock's one-year return stands at 26.4%. The GekkoIndex reads 61.2, placing it in the Accumulation zone, and the price remains 14.1% below the Gekko Fair Value of $1,018.50.
This week's coverage centers on McKesson's raised full-year EPS guidance, now set at $44.20 to $45.00, following first-quarter strength across its North American Pharmaceutical, Oncology & Multispecialty, and Prescription Technology Solutions segments. Alongside the guidance increase, the company disclosed plans to rebrand its Medical-Surgical unit as Wellverse, with a potential IPO eyed for late 2027, and announced an agreement to acquire Precision Medicine Group to expand its oncology and biopharma services. Commentary also referenced McKesson's presentation at the Morgan Stanley 24th Annual Global Healthcare Conference.
Looking ahead, McKesson's next earnings report is scheduled for 4 November 2026, 45 days out and beyond a typical 20-trading-day holding window. Over the last 90 days, Congress members recorded 3 buys and 0 sells. Seasonally, the next 20 trading days have averaged a 3.8% gain over 5 years, rising in 3 of them. Among 13 covering analysts, 10 rate the stock buy and 3 hold, with a consensus target of $980.73 implying 12.1% upside.
Written by AI and checked automatically against the figures on this page. Generated Sep 20, 2026 from the data above.
Price vs fair value
Close $874.65200-day averageGekko Fair Value $1,018.50
Key stats
- Market cap
- $102.4B
- P/E ratio
- 23.8
- Forward P/E
- 19.9
- EPS, TTM
- $36.94
- Revenue, TTM
- $411.0B
- Profit margin
- 1.1%
- Dividend yield
- 0.37%
- Beta
- 0.31
- Volume
- 2.66M avg 948,617
- 1-year return
- +26.4%
- Typical daily move
- ±2.4%
- Typical 20-day move
- ±4.6%
- 50-day average
- $866.63
- 200-day average
- $844.14
- Next earnings
- Nov 4 after close
- Shares outstanding
- 116.6M
McKesson swing-trade checklist
McKesson scores 6 supportive, 0 mixed and 0 headwinds across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
6 supportive0 mixed0 headwinds
- Trendsupportive
Above 50 and 200-day
Close $874.65 is above the 50-day ($866.63) and 200-day ($844.14) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexsupportive
61.2, Accumulation
Reading 61.2 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
14.1% below
Price is 14.1% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneysupportive
Leans bullish
Last 90 days: Congress 3 buys / 0 sales.
See smart money - Earnings risksupportive
Reports in 45 days
Next report Nov 4, 2026, 45 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+3.8% on average
From this point in the calendar, the next 20 trading days averaged +3.8% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
McKesson stock chart and price history
McKesson closed at $874.65 on Sep 18, 2026, +26.4% over the past year, inside a 52-week range of $687.68 to $999.00.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +2.5%
- 3 months
- +16.5%
- 6 months
- −2.7%
- 1 year
- +26.4%
The full MCK chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open MCK in Gekko
Follow McKesson through every session
Put MCK on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track MCK in GekkoFree for 7 days. No credit card required.
About McKesson
McKesson distributes pharmaceutical and other healthcare products, working with pharmacies, medical practices, and healthcare providers across the United States and abroad. It handles branded, generic, specialty, biosimilar, and over-the-counter medicines, and is also known for supporting oncology and specialty practices with management tools, technology, and clinical guidance.
The company runs through four segments. Its U.S. Pharmaceutical business supplies medicines and offers consulting, outsourcing, and software services to pharmacies. A separate international segment distributes products and provides support to wholesale, institutional, and retail customers in thirteen European countries and Canada. The Medical-Surgical Solutions unit supplies medical-surgical products and logistics support to healthcare providers, while the Prescription Technology Solutions segment works with biopharmaceutical and life sciences companies to help patients access and stay on medications, linking pharmacies, providers, payers, and drugmakers, and adding third-party logistics and wholesale distribution services.
McKesson traces its founding to 1833 and is headquartered in Irving, Texas. Its shares are listed on the NYSE under the ticker MCK.
- Listed
- NYSE
- Sector
- Distribution services
- Industry
- Medical distributors
- Website
- mckesson.com
McKesson GekkoIndex: the smart money zone
McKesson’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 61.2, in the Accumulation zone, up 3.6 points over five sessions.
61.2Accumulation
Up 3.6 points over five sessions, from the Neutral zone.
Reading for Sep 18, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 23 | −0.2% | −0.6% | ||
| Accumulation (current zone) | 154 | +0.4% | −0.2% | ||
| Neutral | 431 | +0.8% | +3.7% | ||
| Distribution | 48 | −1.3% | −2.4% | ||
| Selling | 6 | Too few readings yet | |||
Average MCK share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.3% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the MCK price, zone by zone.Track MCK in Gekko
Is McKesson stock overvalued? Gekko Fair Value
McKesson trades 14.1% below Gekko Fair Value of $1,018.50, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what McKesson shares are worth, recalculated every trading day.
$1,018.50
Gekko Fair Value, Sep 19, 2026
14.1% Undervalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open MCK in Gekko
McKesson insider and Congress trading
No open-market insider purchases were filed for McKesson, and members of Congress disclosed 3 purchases and 0 sales, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
3trades disclosed: 3 purchases and 0 sales.
| Member | Amount | Disclosed |
|---|---|---|
| Ro Khanna House, CA, purchase | $1,001 - $15,000 | Sep 7 traded Aug 10 |
| Rick Larsen House, WA, purchase | $1,001 - $15,000 | Jul 13 traded Jul 8 |
| Richard Ray Larsen House, WA, purchase | $1,001 - $15,000 | Jul 13 traded Jul 7 |
From congressional disclosures, which report amounts as ranges.
Buybacks
McKesson has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2026
- $2.53B
- As a share of market cap
- 2.47%
- Trailing four quarters
- $6.46B
From company filings.
Hedge funds and billionaires quarter ended Jun 30
2of the funds Gekko tracks hold MCK.
1added0opened1trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko
McKesson earnings: next date and track record
McKesson reports on Nov 4, 2026, after the close (45 days away), and beat the EPS estimate in 8 of its last 8 reports.
Next earnings report
Nov 4, 2026
Expected after the close, 45 days away
- EPS estimate
- $10.72
- Revenue estimate
- $109.9B
8 of 8reports beat the EPS estimate
±5.9%average move across the report
4 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 5, 2026 AI summary
- What they said
- McKesson reported Q1 FY27 revenues up 8% to $105 billion with adjusted EPS of $9.93, a 20% increase, both exceeding expectations. Three of four reporting segments delivered double-digit operating profit growth. The company serves 14,000+ providers across oncology/multispecialty platforms and is expanding AI capabilities and cell/gene therapy access through Inspira-Gene.
- Guidance
- McKesson raised full-year adjusted EPS guidance to $44.20-$45.00, up from prior range of $43.80-$44.60, reflecting confidence from strong Q1 performance and broad-based momentum across the enterprise.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 5, 2026 | $9.93 est $9.44 | $105.4B est $103.9B | +4.9% |
| May 7, 2026 | $11.69 est $11.57 | $96.30B est $101.3B | −1.0% |
| Feb 4, 2026 | $9.34 est $9.17 | $106.2B est $105.8B | +12.5% |
| Nov 5, 2025 | $9.86 est $9.03 | $103.2B est $104.1B | +2.0% |
| Aug 6, 2025 | $8.26 est $8.14 | $97.83B est $96.18B | −6.5% |
| May 8, 2025 | $10.12 est $9.83 | $90.82B est $94.30B | −4.0% |
| Feb 5, 2025 | $8.03 est $7.99 | $95.29B est $96.05B | −0.6% |
| Nov 6, 2024 | $7.07 est $6.87 | $93.65B est $89.33B | +15.7% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
McKesson stock forecast and analyst price targets
Analysts’ average 12-month price target for McKesson is $980.73, +12.1% from the last close, from 13 firms rating the stock in the last 90 days.
$980.73consensus 12-month target, +12.1% from the last close
Now $874.65Avg $980.73
Low $845High $1,080
Each firm’s latest rating in the last 90 days: 13 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 18 | Morgan Stanley | $977 | +11.7% |
| Sep 16 | Bank of America Securities | $1,050 | +20.0% |
| Sep 15 | Evercore ISI | $1,000 | +14.3% |
| Sep 15 | Bank of America Securities | $1,050 | +20.0% |
| Sep 14 | RBC Capital | $845 | −3.4% |
−0.2%average 20-day move after past Accumulation readings
+3.8%average move over the next 20 trading days in the last 5 years
±2.4%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
McKesson seasonality: the next 20 trading days
Over the next 20 trading days from Sep 19, McKesson averaged +3.8% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +0.9% | 3 of 5 |
| Next 10 trading days | +0.2% | 2 of 5 |
| Next 15 trading days | +2.4% | 2 of 5 |
| Next 20 trading days | +3.8% | 3 of 5 |
| Next 30 trading days | +6.8% | 4 of 5 |
For scale, MCK’s typical 20-trading-day move in either direction is about 4.6%.
McKesson market cap and key statistics
McKesson’s market cap is $102.4B, with a P/E ratio of 23.8 and revenue of $411.0B over the last twelve months.
Valuation
- Market cap
- $102.4B
- P/E ratio
- 23.8
- Forward P/E
- 19.9
- EPS, TTM
- $36.94
- Gekko Fair Value
- $1,018.50
Trading
- Volume
- 2.66M
- Avg volume, 20 days
- 948,617
- 52-week high
- $999.00
- 52-week low
- $687.68
- Shares outstanding
- 116.6M
Financials
- Revenue, TTM
- $411.0B
- Profit margin
- 1.1%
- Return on equity
- 0%
- Quarterly earnings growth, YoY
- −17.6%
Risk and income
- Beta
- 0.31
- Typical daily move
- ±2.4%
- Typical 20-day move
- ±4.6%
- Dividend yield
- 0.37%
McKesson stock news this week
Coverage of McKesson this week reads positive: 4 positive, 2 neutral and 2 negative headlines.
- Nykredit A S Buys Shares of 48,302 McKesson Corporation $MCKDefense World, Sep 19
- McKesson (MCK) Sees a More Significant Dip Than Broader Market: Some Facts to KnowYahoo Finance, Sep 16
- Here’s How Much You Would Have Made Owning McKesson Stock In The Last 5 YearsBenzinga, Sep 15
- McKesson Corp. stock outperforms competitors despite losses on the dayMarketWatch, Sep 15
- Does Raised EPS Guidance Change The Bull Case For McKesson Stock (MCK)?Simply Wall Street, Sep 15
- Bank of America Corp DE Acquires New Stake in McKesson Corporation $MCKDefense World, Sep 15
McKesson peers
McKesson’s 3 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| CORCencora | Accumulation | 28.7% below |
| CAHCardinal Health | Accumulation | 41.8% below |
| HSICHenry Schein | Buying | 0.1% above |
A peer links to its own page where one exists.
McKesson stock FAQ
What is McKesson’s market cap?
McKesson’s market cap is $102.4B at the Sep 18, 2026 close of $874.65, with 116.6M shares outstanding. The shares trade on a P/E ratio of 23.8.
What is the McKesson stock forecast?
The consensus analyst 12-month price target for McKesson is $980.73, +12.1% from the last close. Of the 13 firms that rated the stock in the last 90 days, 10 rate it a buy, 3 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is McKesson stock overvalued or undervalued?
On Gekko’s estimate McKesson is undervalued: the Sep 18, 2026 close of $874.65 is 14.1% below Gekko Fair Value of $1,018.50. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does McKesson report earnings next?
McKesson is expected to report on Nov 4, 2026, after the market closes (45 days away). Analysts expect earnings of $10.72 per share on revenue of $109.9B. McKesson beat the earnings estimate in 8 of its last 8 reports, moving 5.9% on average across the report.
What is McKesson’s 52-week high and low?
McKesson’s 52-week high is $999.00 and its 52-week low is $687.68; it closed at $874.65 on Sep 18, 2026, +26.4% over the past year.
Is McKesson stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 6 of the 6 items with data read as supportive (trend, gekkoindex, fair value, smart money, earnings risk and seasonality). The checklist is a description of current data, not a recommendation.
How this page works
Prices and signals update after every US market close; the GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See McKesson the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,349 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.